Drug Screening System Method Comparison

Last updated: September 26, 2024
Sponsor: Intelligent Bio Solutions Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Fingerprint sweat laboratory analysis

Fingerprint sweat drug screen

Clinical Study ID

NCT06618183
IBS-2024-02
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Prospective, open-label, single-dose, randomized, multi-site performance evaluation of the accuracy and usability Intelligent Fingerprinting Drug Screening System in the hands of intended users: "operators" and "donors."

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Informed of the nature of the study, agreed to, and able to read, review, and signthe informed consent document prior to dosing. The informed consent document will bewritten in English; therefore, the subject must have the ability to read andcommunicate in English.

  2. *Completed the screening process within 30 days prior to dosing. Subjects screenedas a part of an IRB-approved General Screening Protocol at the clinical researchsite may be included in this study without additional screening procedures, providedall the required screening procedures have been performed within 30 days prior todosing.

  3. Healthy male and non-pregnant female subjects from ages 18 to 65, inclusive, at thetime of dosing.

  4. *Body mass index (BMI) from 18 kg/m2 to 30 kg/m2, inclusive, and weigh at least 60kg.

  5. *Females of childbearing potential must be willing to practice an acceptable form ofcontraception (see Section 9.3.3), and have a negative urine pregnancy test onadmission to the treatment phase of the study.

  6. *Males must agree to practice an acceptable form of contraception.

  7. *Judged by the Investigator and/or designee to be in good health as documented bythe medical history, and vital sign assessments. Any abnormalities or deviationsoutside the normal range for vital signs can be repeated by clinical staff andjudged to be not clinically significant for study participation.

Exclusion

Exclusion Criteria:

  1. Unwilling or unable to provide informed consent.

  2. *More than three digits absent from the hands due to congenital or accidentalcause(s).

  3. *Reports receiving any investigational drug within 30 days prior to dosing.

  4. *Reports a clinically significant illness during the 30 days prior to the in-clinicportion of the study (as determined by the Investigator).

  5. *Reports any personal history of substance abuse (including drug/alcohol abuse oraddiction) or mental illness (e.g. major depression) within one year prior toscreening visit.

  6. *Is pregnant (females only).

  7. *Presence of any clinically significant results from laboratory tests and vitalsigns assessments, as judged by the Investigator.

  8. *Reports history of respiratory depression (e.g., sleep apnea).

  9. *Current severe hypotension (i.e., systolic blood pressure <90 mmHg).

  10. *Reports known or suspected gastrointestinal obstruction including, paralytic ileus.

  11. *Reports current presence of acute bronchial asthma/ upper airway obstruction.

  12. *Reports a history of clinically significant allergies, including food or drugallergies, as judged by the Investigator.

  13. *Reports history or current condition of adrenal insufficiency.

  14. *Reports history or current condition of renal disease.

  15. If, in the opinion of the Investigator, the subject is not suitable for the study.

  • Required only for "donors." Not required for "operators."

Study Design

Total Participants: 135
Treatment Group(s): 2
Primary Treatment: Fingerprint sweat laboratory analysis
Phase:
Study Start date:
August 26, 2024
Estimated Completion Date:
December 31, 2024

Study Description

This study will compare positive and negative test results obtained from fingerprint sweat using the Intelligent Fingerprinting DSC-7 Drug Screening Cartridge versus opiates in sweat collected via the Fingerprint Collection Kit for Laboratory Analysis, within healthy males and non-pregnant females.

The primary objective is to compare the sensitivity, specificity, and accuracy of the Intelligent Fingerprinting Drug Screening System to the validated confirmatory LC-MS/MS technique.

The secondary objectives are to assess drug screening system usability and reproducibility.

"Operators" comprise nine (9) adults: male and female subjects who operate the drug screening system. These subjects are not administered any drug. "Operators" represent end users who utilize the screening system in a laboratory setting. "Operators" will be provided the Intelligent Fingerprinting Drug Screening Guide, Confirmatory Laboratory Analysis Guide, and Quick Reference Guide, and be trained in system use. After receiving and reviewing all materials, the "operator" will complete a Training Exam to determine if he or she may proceed with testing.

"Donors" comprise 135 healthy adults: male and non-pregnant female subjects who provide fingerprint sweat specimens. Subjects will be randomized into the blocks administered 0, 30, or 60mg of codeine sulfate in tablet form. "Donors" represent end users either applying for employment or working at an organization that conducts pre-employment and/or periodic workplace drug screening.

Connect with a study center

  • CenExel iResearch

    Decatur, Georgia 30030
    United States

    Active - Recruiting

  • CenExel HRI

    Berlin, New Jersey 08009
    United States

    Active - Recruiting

  • CenExel HRI

    Marlton, New Jersey 08053
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.